QUOTE AND NEWS
Benzinga  Feb 3  Comment 
The Medicines Company (NASDAQ: MDCO) announced on Wednesday that it has appointed Dr. Alexander Denner to its Board of Directors. Denner is the Chief Investment Officer of Sarissa Capital Management, a registered investment advisor. Denner...
Benzinga  Jan 22  Comment 
The share price of The Medicines Company (NASDAQ: MDCO) has appreciated 41.79 percent over the past year, from $27.50 on January 22, 2015. JPMorgan’s Jessica Fye has reiterated an Overweight rating on the company, with a price target of...
Motley Fool  Jan 21  Comment 
Unnamed sources say the drug company is selling some or all of its assets.
Benzinga  Jan 20  Comment 
Shares of The Medicines Company (NASDAQ: MDCO) continued higher on Wednesday, by as much as double-digit percentage points in early trading. The stock initially surged higher late Tuesday afternoon. Following a brief parabolic move,...
FierceBiotech  Jan 20  Comment 
Drugmaker the Medicines Company saw its shares rise as high as 14% on rumors that the company may be up for sale.
Benzinga  Jan 20  Comment 
The Medicines Company (NASDAQ: MDCO) shares rose 12.88 percent to $35.57. The volume of Medicines Company shares traded was 295 percent higher than normal. On Tuesday, Benzinga reported Mallinckrodt PLC (NYSE: MNK) may be interested in a deal...
Benzinga  Jan 19  Comment 
Shares of The Medicines Company (NASDAQ: MDCO) made a mysterious parabolic move in Tuesday's afternoon session. At 3:00 p.m. ET, the stock spiked up to the $31.40 level after nearly falling below $31 during the day. Shares of Medicines Company...
Benzinga  Dec 15  Comment 
The Medicines Company (NASDAQ: MDCO) today announced that the European Heart Journal – Cardiovascular Pharmacotherapy has published results of its Phase 1 study for MDCO-216, a compound under development for the reduction of...




RELATED WIKI ARTICLES
 

Based in Parsippany, NJ, The Medicines Company (MDCO) is engaged in acquiring, developing, and marketing specialty pharmaceutical primarily for cardiovascular indications. Its leading product, Angiomax (bivalirudin), which was acquired from Biogen Idec, Inc. in 1996, is used as an anticoagulant in patients undergoing coronary angioplasty. The company's other late-stage products include Clevidipine and Cangrelor, both acquired from AstraZeneca several years ago. Clevidipine is an intravenous drug (calcium channel blocker) intended for the short-term control of blood pressure in patients undergoing cardiac surgery. Cangrelor is an intravenous anticoagulant, having potential uses in coronary angioplasty and cardiac surgery. The company sells its products through its own sales force and distributors. In 2006, sales of Angiomax helped generate $214.0 million revenue.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki